Deciphera Pharmaceuticals/DCPH

$16.61

-4.32%
-
1D1W1MYTD1YMAX

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on discovering, developing, and commercializing medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The Company has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.

Ticker

DCPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Hoerter

Employees

355

Headquarters

Waltham, United States

DCPH Metrics

BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$2.29
EPS
0.39
Beta
-
Dividend rate

What the Analysts think about DCPH

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 11 analysts.
37.39% upside
High $34.00
Low $9.00
$16.61
Current price
$22.82
Average price target

DCPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-97.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$48.2M
11.32%
Net income
$-47.1M
-4.85%
Profit margin
-97.71%
-14.52%

DCPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.97%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.60
-$0.57
-$0.58
-$0.54
-
Expected
-$0.59
-$0.62
-$0.61
-$0.58
-$0.56
Surprise
1.15%
-8.06%
-4.73%
-6.97%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Deciphera Pharmaceuticals stock

Buy or sell Deciphera Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing